Impactos da venlafaxina na espermatogênese e fertilidade masculina: revisão sistemática em modelo experimental

Abstract

Antidepressant medications are commonly used in men of reproductive age for the long-term treatment of depression, as well as other disorders. Although antidepressants are associated with negative sexual effects, such as reduced libido, sexual impotence, anorgasmia or ejaculatory delay, the literature lacks clear evidence on the role of this therapy on male fertility. Venlafaxine is a serotonin and noradrenaline reuptake inhibitor antidepressant with high efficacy and tolerability, being widely used in clinical practice. Thus, our aim was to review and analyze the impact of venlafaxine on aspects of male fertility using experimental male murine models through a systematic review. To do so, we conducted a survey in three literature databases. Initially, we found 84 articles in searches by title and abstract on PubMed (n = 6), Embase (n = 47) and Scopus (n = 31) platforms. As inclusion criteria, we considered controlled and randomized studies in male mice, submitted to the use of venlafaxine, covering all languages and an open period. In the exclusion criteria, we considered the presence of comorbid diseases and studies in females. After removal of duplicates and thorough and complete analysis, 9 articles were included in this review. The implied results showed a negative impact on sperm concentration, hormonal dysregulation, changes in the histoarchitecture of the reproductive system, and a large increase in oxidative stress. In conclusion, we observed that venlafaxine negatively affects the fertility of male mice.